Vetigenics Secures $6M Seed Round to Revolutionize Pet Health with Next-Gen Canine Immunotherapies

Vetigenics is thrilled to announce that the company has successfully raised $6,000,000 to further advance its groundbreaking work in pet health biotechnology. Harnessing the power of the animal's own immune system, Vetigenics is at the forefront of transforming veterinary medicine through innovative approaches that improve the lives of our cherished companions. Founded by esteemed experts Nicola Mason BVetMD, PhD and Don Siegel PhD, MD from the University of Pennsylvania, the company has developed the only comprehensive, canine single chain fragment variable (scFv) phage display libraries, boasting a remarkable repertoire of over 40 billion unique scFv members. These libraries provide the foundation for CANIBODIES™, a revolutionary platform comprised entirely of canine scFvs. These antibodies are uniquely selected based on their antigen-binding capabilities, functionality, and developability; because they are derived from native canine immunoglobulin germline genes, they avoid the challenges of caninization or chimeric design and offer significantly reduced immunogenicity compared to antibodies produced by traditional methods. The recent funding injection will be strategically allocated to accelerate the development and refinement of CANIBODIES™ and to explore additional therapeutic formats such as full-length canine IgGs, BiTEs, and CAR-T cell constructs. This expansion is aimed at not only enhancing Vetigenics’ current portfolio but also positioning the company to address unmet needs in both animal and potentially human health. With the support of a wide network of industry experts, Vetigenics is committed to driving forward innovative solutions that promise to improve wellness and extend the quality of life for pets everywhere. For further information about this announcement, please contact Adriann Sax, CEO, at asax@vetigenics.com.